MIMEDX GROUP INC (MDXG)
Health Care · Biotechnology / Regenerative Medicine · NASDAQ
MiMedx is a regenerative medicine company specializing in placental tissue-based therapies for advanced wound care and surgical applications.
What MIMEDX GROUP INC does
MiMedx Group is a biopharmaceutical company that develops and markets regenerative medicine products and therapies, primarily utilizing human placental tissue. The company’s portfolio is centered on advanced wound care solutions, addressing complex wound management needs. Its products are widely used in medical settings to facilitate tissue repair and healing.
Themes: regenerative medicine, advanced wound care, placental tissue therapy
Fundamentals
- Price$4.33 as of 2026-08-21 close
- Market cap$631M as of 2026-08-21
- 1-year return-38.4% 2025-08-21 close $7.03 → 2026-08-21 close $4.33
- P/E98.12 as of 2026-08-24
- Net margin+1.8% as of 2026-08-24
- Gross margin+78.8% as of 2026-08-24
- ROE+2.6% as of 2026-08-24
- Debt / equity0.08 as of 2026-08-24
- Revenue growth (YoY)-2.4% as of 2026-08-24
- Revenue CAGR (3y)+16.1% SEC XBRL
- Beta1.22 as of 2026-08-24
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How MDXG compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MIMEDX GROUP INC looks technically
MIMEDX GROUP INC (MDXG) is trading 12.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 146 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago. It is 45.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 12.0% below its 200-day average, the long-term trend line — a long-term downtrend | -12.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.10 | $4.10 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.92 | $4.92 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 4.12. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 146 trading days ago — a "death cross", a bearish long-term signal | 146 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 54.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.05 to $4.50) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 62.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.97 | $7.97 |
|---|---|---|
| From the 52-week high | it is 45.7% below its 52-week high (its highest price of the past year) | -45.7% |
| Above the 52-week low | it is 43.1% above its 52-week low (its lowest price of the past year) | +43.1% |
| Below the 52-week high | it is 45.7% below its highest point of the past year | 45.7% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $18.25 (set on 2018-01-29) | $18.25 |
| Given back of the 52-week move | over the past year its closes ranged ($3.08 to $7.96), and it has recovered roughly a quarter of its fall from last year’s high — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.10 to $6.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 25.5% |
| From the all-time high | it is 76.3% below its all-time high | -76.3% |
| Nearest price level | it is trading 3.2% below a resistance level at $4.47 — a price it turned at twice since 2026-07-16, most recently on 2026-08-03. Since 2024-08-21 it has 3 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.2% |
| All-time low | its lowest closing price on record is $0.3086 (set on 2007-08-22) | $0.3086 |
| Above the all-time low | it is 1302.9% above its all-time low | +1,303% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1744 between its high and its low — about 4.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1744 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.12 and $4.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.12 – $4.27 – $4.42 |
| Typical daily range (% of price) | its price moves about 4.0% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.0% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges below its 200-day average price (12.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.65× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 7.8% gap down opened on 2026-07-30 has been "filled" 16 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 16 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.1 percentage points (the stock gained 0.2% while the market gained 2.3%) | -2.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.8 percentage points (the stock gained 19.9% while the market gained 3.1%) | +16.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 27.3 percentage points (the stock lost 16.2% while the market gained 11.1%) | -27.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 58.9 percentage points (the stock lost 38.4% while the market gained 20.5%) | -58.9% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.9% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +5.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.18 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +3.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $4.26 — a volume-weighted average of daily closes over 18 sessions, not a true tick-by-tick VWAP. | +1.7% |
Price levels it has turned at before
MDXG last closed at $4.33 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 14 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $4.47 | Resistance | 3.2% above the last close | turned there twice · 2026-07-16 to 2026-08-03 |
| $4.11 | Support | 5.2% below the last close | turned there twice · 2026-07-22 to 2026-08-14 |
| $3.77 | Support | 13.1% below the last close | turned there four times · 2026-03-30 to 2026-07-30 |
| $3.46 | Support | 20.0% below the last close | turned there twice · 2026-05-13 to 2026-06-01 |
| $5.46 | Resistance | 26.2% above the last close | turned there twice · 2024-10-10 to 2026-02-24 |
| $5.61 | Resistance | 29.6% above the last close | turned there twice · 2024-09-26 to 2024-10-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $4.12.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $4.84 and $5.29 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $4.12.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$7.00 range $6.00 – $8.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDXG
- Consensus EPS estimate$0.00667 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Changes in Medicare reimbursement policies for skin substitutes which may negatively impact product demand.","Significant dependence on regulatory and legal environments for product classification and market access.","Intense competition and potential for declining net sales."]
What changed in the latest 10-Q
AI-assisted comparison of MDXG's 10-Q filed 2026-04-29 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Q1 2026 filing mentions launch of two new products: AMNIOFIX® Thyroid Shields and CHORIOFIX™
- Q1 2026 filing mentions exclusive distribution agreement with Summit Products Group for G4Derm® Plus, Hydrelix Collagen Matrix and Novaform®
- Q1 2026 filing references Annual Report on Form 10-K for fiscal year ended December 31, 2025 filed February 25, 2026
- Q1 2026 filing includes detailed line item for 'Amortization of intangible assets' in results table ($301k vs $99k)
- Q1 2026 filing includes discussion of Medicare reimbursement changes effective January 1, 2026 impacting Wound Care pricing and volumes
- Q1 2026 filing mentions 'RegenKit PRP offering' as initial contribution to Wound sales
- Q1 2026 filing discusses reversal of stock-based compensation expense associated with performance stock unit awards
- Q1 2026 filing mentions 'ongoing litigation with certain competitors and certain former employees'
- Removed:
- Q3 2025 filing included 'Reimbursement Update' section with detailed discussion of proposed CMS rules and comment periods
- Q3 2025 filing mentioned 'Wasteful and Inappropriate Service Reduction model'
- Q3 2025 filing included separate line item 'Investigation, restatement and related' expense ($0 in 2025, $649k in 2024)
- Q3 2025 filing included separate line item 'Impairment of intangible assets' ($0 in 2025, $298k in 2024)
- Q3 2025 filing referenced 'turnover of certain sales team and customers' and 'commercial challenges associated with competitive behavior'
- Q3 2025 filing mentioned specific product names CELERA and EMERGE as drivers of growth
- Q3 2025 filing discussed 'positive production variances' as driver of gross margin improvement
- Reworded:
- Overview section changed from 'With more than a decade of experience helping clinicians manage acute and chronic wounds' to 'more than a decade and a half of experience developing and commercializing products'
- Overview removed reference to 'wound care, burn, and surgical sectors' and changed to 'Surgical and Wound management applications'
- Surgical product growth drivers changed from 'AMNIOFIX and AMNIOEFFECT, as well as continuing commercial uptake of HELIOGEN' to 'AMNIOFIX®, AMNIOEFFECT®, AXIOFILL®, and HELIOGEN™' with 'adoption expanded across multiple surgical procedures'
- Gross profit margin decline explanation changed: Q1 2026 cites 'Medicare reimbursement changes' and 'unfavorable product mix and higher costs' versus Q3 2025 which cited 'positive production variances and product mix'
- SG&A expense characterization changed from increases in both S&M and G&A in Q3 2025 to decreases in both categories in Q1 2026
- Notes:
- The two filings cover different quarterly periods (Q1 2026 vs Q3 2025) and different prior-year comparisons, making some comparisons structural rather than substantive
- The Q1 2026 filing appears truncated at the end of the 'Discussion of Cash Flows' section, limiting full assessment of that section
Risk Factors
- Added:
- Two new bullet points in forward-looking statements: (1) 'our expectations regarding demand for our Wound products in response to recent changes in Medicare reimbursement for skin substitutes' and (2) 'our expectations of the impact of our cost reduction initiatives' (filed 2026-04-29)
- Reference to '2025 Form 10-K' filed February 25, 2026 in risk factors discussion (filed 2026-04-29)
- Removed:
- Bullet point stating 'our expectations regarding costs relating to compliance with regulatory requirements' moved from forward-looking statements list (filed 2025-10-29)
- Reference to '2024 Form 10-K' filed February 26, 2025 replaced with 2025 Form 10-K reference (filed 2026-04-29)
- Reworded:
- Forward-looking statements disclaimer now references 'our Annual Report on Form 10-K for the year ended December 31, 2025' instead of 'year ended December 31, 2024' (filed 2026-04-29)
- Index page numbers for Item 1A Risk Factors changed from 25 to 22 across all subsequent items (filed 2026-04-29)
- Notes:
- The two filings are for different fiscal periods (Q1 2026 vs Q3 2025) and therefore include different financial statements and period-specific disclosures; comparison focuses only on the Risk Factors section introductory material and forward-looking statements language as presented
- Financial data tables are presented for context but are not part of the Risk Factors section comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for MDXG — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MDXG as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 20,856,086
- Reported value $82,381,540
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
MDXG had 8,434,992 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
MDXG had 5.79% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.32 days to cover at the same settlement.
- Reported short interest (shares) 8,434,992
- Short interest (% of shares outstanding) 5.79%
- Prior settlement (shares) 7,521,566
- Reported change 12.14%
- Days to cover (reported) 5.32
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Organogenesis (ORGO)
- Smith & Nephew
- Integra LifeSciences (IART)
- ConvaTec
- Amniox Medical
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDXG vs…
MIMEDX GROUP INC is found in…
Frequently asked questions
What does MIMEDX GROUP INC (MDXG) do?
MiMedx Group is a biopharmaceutical company that develops and markets regenerative medicine products and therapies, primarily utilizing human placental tissue. The company’s portfolio is centered on advanced wound care solutions, addressing complex wound management needs. Its products are widely used in medical settings to facilitate tissue repair and healing.
What sector is MIMEDX GROUP INC (MDXG) in?
MIMEDX GROUP INC (MDXG) is classified in the Health Care sector. Its industry is Biotechnology / Regenerative Medicine. It trades on NASDAQ.
Who are MIMEDX GROUP INC's (MDXG) competitors?
Notable peers of MIMEDX GROUP INC (MDXG) include Organogenesis, Smith & Nephew, Integra LifeSciences, ConvaTec and Amniox Medical. This peer set is informational only — not financial advice.
Is MIMEDX GROUP INC (MDXG) overbought or oversold right now?
MIMEDX GROUP INC (MDXG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDXG come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.